Comanche Biopharma Corp. — Form D
Comanche Biopharma Corp. of CONCORD, MA, a company, filed a Form D exempt-offering notice with the SEC on 2023-05-12. The offering totals $36.1M, of which $36.1M was reported sold. Industry: Pharmaceuticals.
Offering
- Filed: 2023-05-12
- Form: D
- Accession: 0001873062-23-000001
- Industry: Pharmaceuticals
- Exemptions: 06b
- Total offering: $36.1M
- Amount sold: $36.1M
- Investors: 7
- Date of first sale: 2021-06-28
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-481558
Issuer
- Name: Comanche Biopharma Corp.
- CIK: 0001873062
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2020
- Address: 50 Beharrell Street, CONCORD, MA, 01742
- Phone: 617-206-3776
Officers, directors & promoters (14)
| Name | Role | Location |
|---|
| Arthur Scott Levin | Director | Concord, MA |
| Clive Scott Meanwell | Director | Concord, MA |
| Ann Scott Taylor | Director | Concord, MA |
| Brendan Scott Bulik-Sullivan | Director | Concord, MA |
| Muzammil Scott Mansuri | Director | Concord, MA |
| Allison Scott August | Executive Officer | Concord, MA |
| Paul Scott Antinori | Executive Officer | Concord, MA |
| Allyson Scott Felix | Director | Concord, MA |
| David Scott Grayzel | Director | Concord, MA |
| Thomas Scott Johnson | Director | Concord, MA |
| Thomas Scott Johnson | Executive Officer | Concord, MA |
| Scott Scott Gottlieb | Director | Concord, MA |
| Ketan Scott Patel | Director | Concord, MA |
| Michael Scott Young | Executive Officer | Concord, MA |
Other filings by this issuer (1)
More